This could unfold like this ... Just an example caught on the fly. You could almost read the Theralase's TLD-1433 story versus Merck's BCG in few months ...
It just to show that things could turn on a dime when large pool of patients clinical data is out and is seen as superior to SoC.
"Our point here is not to argue the validity of Biogen's data but to point out, by comparison, how compelling the Anavex data looks to us," on all studies, from animal to recent clinical ones, he noted.
Anavex is currently in a Phase 2b/3 trial, which could be done by year-end 2020. If so, commercialization could ensue by the end of 2022, he stated.
Kolbert highlighted that ANAVEX2-73 has a different mechanism of action in Alzheimer's disease than aducanumab. Rather than focus on beta amyloid, it targets and activates the Sigma-1 receptor. "It is believed that Sigma 1 can help to protect a cell from the accumulation of misfolded proteins, acting to chaperone them out of the cell. As a result, cell metabolism (oxidative stress and mitochondrial dysfunction) are kept in balance." Accordingly, it could have "an impact across a wide range of neurodegenerative diseases from Alzheimer's to Parkinson's and niche orphan diseases such as Rett syndrome, which may represent a 'fast path' to establish proof of concept, around Sigma-1 agonism," Kolbert commented.
Dawson James has a Buy rating and a $16 per share target price on Anavex. The stock is currently trading at around $2.38 per share.